News

Public · Published

OLN: FY 2026 adjusted EBITDA guidance is $550M–$570M as merger preparations accelerate

Olin's third-quarter operations faced VCM downtime, cost inflation, and volatile chemical markets. Winchester demand and military awards were stronger. The company set full-year 2026 adjusted EBITDA guidance, a rough profit measure, at $550 million to $570 million, with its Huntsman merger targeted to close in the first quarter of 2027.

Published:

Updated:

What happened

Olin's third-quarter operations faced VCM downtime, cost inflation, and volatile chemical markets. Winchester demand and military awards were stronger. The company set full-year 2026 adjusted EBITDA guidance, a rough profit measure, at $550 million to $570 million, with its Huntsman merger targeted to close in the first quarter of 2027.

Confirmed

Global impact / market context

The guidance gives investors an expected profit range for 2026, while the Huntsman merger could combine two chemical businesses. Cost inflation and plant downtime at Olin's VCM operations, which make a key chemical input, could pressure profit if they persist, even as Winchester demand supports results.

Analyst inference

Chemical markets remain volatile, and the company is balancing weak VCM operations against stronger Winchester demand tied to military awards. The merger timeline extends into 2027, so investors may weigh near-term profit guidance against execution risk and chemical price swings before the deal closes.

Analyst inference

What to watch

  1. Olin's full-year 2026 adjusted EBITDA guidance of $550 million to $570 million, which means profit before interest, taxes, depreciation, and amortization, sets the range investors will compare with actual results. Confirmed
  2. The Huntsman merger is targeted to close in the first quarter of 2027; watch whether that proposed timeline holds and whether any conditions or delays emerge before completion. Proposed
  3. Watch VCM plant downtime and cost inflation, because continued outages or higher input costs could lower chemical segment revenue and squeeze profit margins relative to the guidance range. Analyst inference

Evidence

  • Original source link unavailable